Login Register Cart 0
Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Effects of Coenzyme Q10 Supplementation on Serum Adiponectin Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Author(s): Ali Nazary-Vannani, Ehsan Ghaedi, Shekoufeh Salamat, Afsaneh Sayyaf, Hamed K. Varkaneh, Hamed Mohammadi and Mahmoud Djalali*

Volume 15, Issue 1, 2020

Page: [3 - 11] Pages: 9

DOI: 10.2174/1574885514666190308162322

Price: $65

Abstract

Background: Adiponectin, a well-known adipokine plays a number of regulatory actions in human body metabolism. Decreased levels of adiponectin have been reported in type 2 diabetes mellitus, cardiovascular diseases, metabolic syndrome and hypertension. Coenzyme Q10 (Co Q10) is a fat-soluble antioxidant substance which has been reported to be effective in several metabolic disturbances such as insulin resistance and inflammation.

Objective: Present systematic review and meta-analysis were performed to assess the effects of CoQ10 supplementation on adiponectin serum level.

Methods: A comprehensive search was performed in electronic databases including EMBASE, Google scholar, and PubMed up to January 2018. A meta-analysis of eligible studies was performed using random effects model to estimate pooled effect size of CoQ10 supplementation on adiponectin.

Results: A total of 209 subjects were recruited from 5 eligible studies. Meta-analysis did not suggest any significant effect of CoQ10 supplementation on adiponectin serum level (0.240 mg/dl, 95%CI: -0.216, 0.696, P= 0.303), without significant heterogeneity between included studies (I2= 40.9%, p= 0.149).

Conclusion: Although present meta-analysis did not indicate any significant effects of CoQ10 supplementation on serum adiponectin levels but future long-term dose-response trials are needed before any firm conclusion.

Keywords: Coenzyme Q10, adiponectin, meta-analysis, diabetes mellitus, adipokine, insulin.

« Previous Next »
Graphical Abstract

[1]
Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: The new endocrine organ? A review article. Dig Dis Sci 2009; 54(9): 1847-56.
[http://dx.doi.org/10.1007/s10620-008-0585-3] [PMID: 19052866]
[2]
Ahima RS. Metabolic actions of adipocyte hormones: Focus on adiponectin. Obesity (Silver Spring) 2006; 14(Suppl. 1): 9S-15S.
[http://dx.doi.org/10.1038/oby.2006.276] [PMID: 16642957]
[3]
Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116(7): 1784-92.
[http://dx.doi.org/10.1172/JCI29126] [PMID: 16823476]
[4]
Lim S, Quon MJ, Koh KK. Modulation of adiponectin as a potential therapeutic strategy. Atherosclerosis 2014; 233(2): 721-8.
[http://dx.doi.org/10.1016/j.atherosclerosis.2014.01.051] [PMID: 24603219]
[5]
Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: Evidence for independent roles of age and sex. Diabetologia 2003; 46(4): 459-69.
[http://dx.doi.org/10.1007/s00125-003-1074-z] [PMID: 12687327]
[6]
Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6(10): 772-83.
[http://dx.doi.org/10.1038/nri1937] [PMID: 16998510]
[7]
Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: Correlations with insulin resistance. Eur J Endocrinol 2003; 149(4): 331-5.
[http://dx.doi.org/10.1530/eje.0.1490331] [PMID: 14514348]
[8]
Sheng T, Yang K. Adiponectin and its association with insulin resistance and type 2 diabetes. J Genet Genomics 2008; 35(6): 321-6.
[http://dx.doi.org/10.1016/S1673-8527(08)60047-8] [PMID: 18571119]
[9]
Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, Libby P. Adiponectin: A key adipocytokine in metabolic syndrome. Clin Sci 2006; 110(3): 267-78.
[http://dx.doi.org/10.1042/CS20050182] [PMID: 16464169]
[10]
Ryo M, Nakamura T, Kihara S, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004; 68(11): 975-81.
[http://dx.doi.org/10.1253/circj.68.975] [PMID: 15502375]
[11]
Swarbrick MM, Havel PJ. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord 2008; 6(2): 87-102.
[http://dx.doi.org/10.1089/met.2007.0029] [PMID: 18510434]
[12]
Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86(5): 1930-5.
[http://dx.doi.org/10.1210/jcem.86.5.7463] [PMID: 11344187]
[13]
Bhagavan HN, Chopra RK. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res 2006; 40(5): 445-53.
[http://dx.doi.org/10.1080/10715760600617843] [PMID: 16551570]
[14]
DiNicolantonio JJ, Bhutani J, McCarty MF, O’Keefe JH. Coenzyme Q10 for the treatment of heart failure: A review of the literature. Open Heart 2015; 2(1): e000326
[http://dx.doi.org/10.1136/openhrt-2015-000326] [PMID: 26512330]
[15]
Moazen M, Mazloom Z, Dabbaghmanesh M, Ahmadi A. Effect of CoQ10 supplementation on blood pressure, inflammation, and lipid profile in type 2 diabetics. Iran J Nutr Sci Food Technol 2013; 8: 145-53.
[16]
Langsjoen PH, Langsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. Biofactors 1999; 9(2-4): 273-84.
[http://dx.doi.org/10.1002/biof.5520090224] [PMID: 10416041]
[17]
Ahmadvand H, Tavafi M, Khosrowbeygi A. Amelioration of altered antioxidant enzymes activity and glomerulosclerosis by coenzyme Q10 in alloxan-induced diabetic rats. J Diabetes Complications 2012; 26(6): 476-82.
[http://dx.doi.org/10.1016/j.jdiacomp.2012.06.004] [PMID: 22795334]
[18]
Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD. Coenzyme Q10 improves blood pressure and glycaemic control: A controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 2002; 56(11): 1137-42.
[http://dx.doi.org/10.1038/sj.ejcn.1601464] [PMID: 12428181]
[19]
Mezawa M, Takemoto M, Onishi S, et al. The reduced form of coenzyme Q10 improves glycemic control in patients with type 2 diabetes: an open label pilot study. Biofactors 2012; 38(6): 416-21.
[http://dx.doi.org/10.1002/biof.1038] [PMID: 22887051]
[20]
Sourris KC, Harcourt BE, Tang PH, et al. Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes. Free Radic Biol Med 2012; 52(3): 716-23.
[http://dx.doi.org/10.1016/j.freeradbiomed.2011.11.017] [PMID: 22172526]
[21]
Fuller B, Smith D, Howerton A, Kern D. Anti-inflammatory effects of CoQ10 and colorless carotenoids. J Cosmet Dermatol 2006; 5(1): 30-8.
[http://dx.doi.org/10.1111/j.1473-2165.2006.00220.x] [PMID: 17173569]
[22]
Shimizu K, Kon M, Tanimura Y, et al. Coenzyme Q10 supplementation downregulates the increase of monocytes expressing toll-like receptor 4 in response to 6-day intensive training in kendo athletes. Appl Physiol Nutr Metab 2015; 40(6): 575-81.
[http://dx.doi.org/10.1139/apnm-2014-0556] [PMID: 25941765]
[23]
Schmelzer C, Lorenz G, Rimbach G, Döring F. In vitro effects of the reduced form of coenzyme Q10 on secretion levels of TNF-α and chemokines in response to LPS in the human monocytic cell line THP-1. J Clin Biochem Nutr 2009; 44(1): 62-6.
[http://dx.doi.org/10.3164/jcbn.08-182] [PMID: 19177190]
[24]
Zhai J, Bo Y, Lu Y, Liu C, Zhang L. Effects of Coenzyme Q10 on markers of inflammation: A systematic review and meta-analysis. PLoS One 2017; 12(1): e0170172
[http://dx.doi.org/10.1371/journal.pone.0170172] [PMID: 28125601]
[25]
Farsi F, Mohammadshahi M, Alavinejad P, Rezazadeh A, Zarei M, Engali KA. Functions of Coenzyme Q10 supplementation on liver enzymes, markers of systemic inflammation, and adipokines in patients affected by nonalcoholic fatty liver disease: A double-blind, placebo-controlled, randomized clinical trial. J Am Coll Nutr 2016; 35(4): 346-53.
[http://dx.doi.org/10.1080/07315724.2015.1021057] [PMID: 26156412]
[26]
Moazen M, Mazloom Z, Ahmadi A, Dabbaghmanesh MH, Roosta S. Effect of coenzyme Q10 on glycaemic control, oxidative stress and adiponectin in type 2 diabetes. J Pak Med Assoc 2015; 65(4): 404-8.
[PMID: 25976576]
[27]
Bagheri NN, Mozaffari-Khosravi H, Najarzadeh A, Salehifar E. The effect of Coenzyme Q10 supplementation on pro-inflammatory factors and adiponectin in mildly hypertensive patients: A randomized, double-blind, placebo-controlled trial. Int J Vitam Nutr Res 2015; 85(3-4): 156-64.
[http://dx.doi.org/10.1024/0300-9831/a000234]
[28]
Lee B-J, Tseng Y-F, Yen C-H, Lin P-T. Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: A randomized, placebo-controlled trial. Nutr J 2013; 12(1): 142.
[http://dx.doi.org/10.1186/1475-2891-12-142] [PMID: 24192015]
[29]
Gökbel H, Gergerlioğlu HS, Okudan N, Gül I, Büyükbaş S, Belviranli M. Effects of coenzyme Q10 supplementation on plasma adiponectin, interleukin-6, and tumor necrosis factor-α levels in men. J Med Food 2010; 13(1): 216-8.
[http://dx.doi.org/10.1089/jmf.2008.0310] [PMID: 20136458]
[30]
Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015; 350: g7647.
[http://dx.doi.org/10.1136/bmj.g7647] [PMID: 25555855]
[31]
Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions 2011.
[32]
Borenstein M, Hedges LV, Higgins J, Rothstein HR. Introduction to meta-analysis, Effect size andpercision 2009; 21-32.
[http://dx.doi.org/10.1002/9780470743386.ch4]
[33]
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327(7414): 557-60.
[http://dx.doi.org/10.1136/bmj.327.7414.557] [PMID: 12958120]
[34]
Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 1999; 47: 15-7.
[35]
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109): 629-34.
[http://dx.doi.org/10.1136/bmj.315.7109.629] [PMID: 9310563]
[36]
Amin MM, Asaad GF, Abdel Salam RM, El-Abhar HS, Arbid MS. Novel CoQ10 antidiabetic mechanisms underlie its positive effect: modulation of insulin and adiponectine receptors, Tyrosine kinase, PI3K, glucose transporters, sRAGE and visfatin in insulin resistant/diabetic rats. PLoS One 2014; 9(2): e89169.
[http://dx.doi.org/10.1371/journal.pone.0089169] [PMID: 24586567]
[37]
James AM, Smith RA, Murphy MP. Antioxidant and prooxidant properties of mitochondrial Coenzyme Q. Arch Biochem Biophys 2004; 423(1): 47-56.
[http://dx.doi.org/10.1016/j.abb.2003.12.025] [PMID: 14989264]
[38]
Bentinger M, Brismar K, Dallner G. The antioxidant role of coenzyme Q. Mitochondrion 2007; 7: S41-50.
[http://dx.doi.org/10.1016/j.mito.2007.02.006] [PMID: 17482888]
[39]
Miles MV. The uptake and distribution of coenzyme Q10. Mitochondrion 2007; 7: S72-7.
[http://dx.doi.org/10.1016/j.mito.2007.02.012] [PMID: 17446143]
[40]
Pravst I, Žmitek K, Žmitek J. Coenzyme Q10 contents in foods and fortification strategies. Crit Rev Food Sci Nutr 2010; 50(4): 269-80.
[http://dx.doi.org/10.1080/10408390902773037] [PMID: 20301015]
[41]
Sohet FM, Delzenne NM. Is there a place for coenzyme Q in the management of metabolic disorders associated with obesity? Nutr Rev 2012; 70(11): 631-41.
[http://dx.doi.org/10.1111/j.1753-4887.2012.00526.x] [PMID: 23110642]
[42]
Kawano J, Arora R. The role of adiponectin in obesity, diabetes, and cardiovascular disease. J Cardiometab Syndr 2009; 4(1): 44-9.
[http://dx.doi.org/10.1111/j.1559-4572.2008.00030.x] [PMID: 19245516]
[43]
Rovin BH, Song H, Hebert LA, et al. Plasma, urine, and renal expression of adiponectin in human systemic lupus erythematosus. Kidney Int 2005; 68(4): 1825-33.
[http://dx.doi.org/10.1111/j.1523-1755.2005.00601.x] [PMID: 16164660]
[44]
Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Voudouri T, Kouroumalis EA. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12(2): 100-5.
[http://dx.doi.org/10.1097/01.MIB.0000200345.38837.46] [PMID: 16432373]
[45]
Otero M, Lago R, Gomez R, et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65(9): 1198-201.
[http://dx.doi.org/10.1136/ard.2005.046540] [PMID: 16414972]
[46]
Kumada M, Kihara S, Ouchi N, et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004; 109(17): 2046-9.
[http://dx.doi.org/10.1161/01.CIR.0000127953.98131.ED] [PMID: 15096450]
[47]
Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin. Circulation 1999; 100(25): 2473-6.
[http://dx.doi.org/10.1161/01.CIR.100.25.2473] [PMID: 10604883]
[48]
Yamaguchi N, Argueta JG, Masuhiro Y, et al. Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett 2005; 579(30): 6821-6.
[http://dx.doi.org/10.1016/j.febslet.2005.11.019] [PMID: 16325814]
[49]
Magalang UJ, Rajappan R, Hunter MG, et al. Adiponectin inhibits superoxide generation by human neutrophils. Antioxid Redox Signal 2006; 8(11-12): 2179-86.
[http://dx.doi.org/10.1089/ars.2006.8.2179] [PMID: 17034361]
[50]
Keller P, Møller K, Krabbe KS, Pedersen BK. Circulating adiponectin levels during human endotoxaemia. Clin Exp Immunol 2003; 134(1): 107-10.
[http://dx.doi.org/10.1046/j.1365-2249.2003.02264.x] [PMID: 12974762]
[51]
Anderson PD, Mehta NN, Wolfe ML, et al. Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab 2007; 92(6): 2272-9.
[http://dx.doi.org/10.1210/jc.2006-2545] [PMID: 17374708]
[52]
Robinson K, Prins J, Venkatesh B. Clinical review: Adiponectin biology and its role in inflammation and critical illness. Crit Care 2011; 15(2): 221.
[http://dx.doi.org/10.1186/cc10021] [PMID: 21586104]
[53]
Ebadi M, Sharma SK, Wanpen S, Amornpan A. Coenzyme Q10 inhibits mitochondrial complex-1 down-regulation and nuclear factor-kappa B activation. J Cell Mol Med 2004; 8(2): 213-22.
[http://dx.doi.org/10.1111/j.1582-4934.2004.tb00276.x] [PMID: 15256069]
[54]
Schmelzer C, Lindner I, Rimbach G, Niklowitz P, Menke T, Döring F. Functions of coenzyme Q10 in inflammation and gene expression. Biofactors 2008; 32(1-4): 179-83.
[http://dx.doi.org/10.1002/biof.5520320121] [PMID: 19096114]
[55]
Kishimoto C, Tomioka N, Nakayama Y, Miyamoto M. Anti-oxidant effects of coenzyme Q10 on experimental viral myocarditis in mice. J Cardiovasc Pharmacol 2003; 42(5): 588-92.
[http://dx.doi.org/10.1097/00005344-200311000-00002] [PMID: 14576505]
[56]
Jankowski J, Korzeniowska K, Cieślewicz A, Jabłecka A. Coenzyme Q10 - A new player in the treatment of heart failure? Pharmacol Rep 2016; 68(5): 1015-9.
[http://dx.doi.org/10.1016/j.pharep.2016.05.012] [PMID: 27428763]
[57]
Dewell A, Marvasti FF, Harris WS, Tsao P, Gardner CD. Low-and high-dose plant and marine (n-3) fatty acids do not affect plasma inflammatory markers in adults with metabolic syndrome. J Nutr 2011; 141: 2166-71.
[58]
Gavrila A, Peng CK, Chan JL, Mietus JE, Goldberger AL, Mantzoros CS. Diurnal and ultradian dynamics of serum adiponectin in healthy men: comparison with leptin, circulating soluble leptin receptor, and cortisol patterns. J Clin Endocrinol Metab 2003; 88: 2838-43.
[59]
Halberg N, Schraw TD, Wang ZV, et al. Systemic fate of the adipocyte-derived factor adiponectin. Diabetes 2009; 58(9): 1961-70.
[http://dx.doi.org/10.2337/db08-1750] [PMID: 19581422]

Rights & Permissions Print Cite
Article Metrics
8
3
© 2024 Bentham Science Publishers | Privacy Policy